Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
hSTC810 + Paclitaxel for Lung Cancer
Recruiting1 awardPhase 1 & 2
Houston, Texas
This trial is testing a new drug (hSTC810) combined with an existing chemotherapy drug (paclitaxel) in patients whose lung cancer has returned or did not respond to previous treatments. The goal is to determine if this combination is safe and effective. Paclitaxel is a well-known chemotherapy drug used to treat lung cancer and has been used in various combinations to improve treatment outcomes and survival times.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service